Get the Stockscreener App
1.60
1.27%
0.02
After Hours:
1.62
0.02
+1.25%
Immix Biopharma Inc stock is traded at $1.60, with a volume of 65,563.
It is up +1.27% in the last 24 hours and down -1.84% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$1.58
Open:
$1.58
24h Volume:
65,563
Relative Volume:
0.55
Market Cap:
$42.00M
Revenue:
-
Net Income/Loss:
$-14.14M
P/E Ratio:
-2.00
EPS:
-0.8
Net Cash Flow:
$-12.64M
1W Performance:
-6.43%
1M Performance:
-1.84%
6M Performance:
-31.91%
1Y Performance:
-55.18%
1-Day Range:
$1.48
$1.60
1-Week Range:
$1.48
$1.71
52-Week Range:
$1.26
$7.75
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Immix Biopharma Inc Stock (IMMX) Latest News
Renaissance Technologies LLC Decreases Stock Holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Immix and Nexcella Make Progress in US Trial for Light Chain Amyloidosis CAR-T NXC-201 - CGTLive™
Immix BiopharmaUS CAR-T trial progresses to dose expansion - Smartkarma
H.C. Wainwright confident in Immix stock growth with progress in NEXICART-2 CAR-T trial - Investing.com
Immix Biopharma’s (IMMX) “Buy” Rating Reiterated at HC Wainwright - Defense World
XTX Topco Ltd Sells 34,534 Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort - GlobeNewswire
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 - StockTitan
Immix Biopharma stock hits 52-week low at $1.51 amid market challenges - Investing.com Australia
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN
Immix Biopharma stock hits 52-week low at $1.74 amid market challenges - Investing.com Australia
Immix Biopharma Announces Dr. Raymond Comenzo, - GlobeNewswire
Immix Biopharma gains AL Amyloidosis expert for advisory board - Investing.com
Immix Biopharma gains AL Amyloidosis expert for advisory board By Investing.com - Investing.com Australia
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board - StockTitan
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update - MarketBeat
It would be worthwhile to take a closer look at Immix Biopharma Inc (IMMX) - US Post News
Its Stock Has Paid Off Big Time For Immix Biopharma Inc - SETE News
The Attractiveness of Investing In Immix Biopharma Inc (IMMX) is Growing - Knox Daily
Immix Biopharma Independent Director Acquires 2.6% More Stock - Yahoo Finance UK
Insider Spends US$52k Buying More Shares In Immix Biopharma - Simply Wall St
Immix Biopharma expands clinical trial sites for AL Amyloidosis therapy - Investing.com
Immix Biopharma expands clinical trial sites for AL Amyloidosis therapy By Investing.com - Investing.com Canada
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - GlobeNewswire
The markets will rise or fall with NVDA - RagingBull
Immix Biopharma director Jason Hsu buys $51,623 in company stock - Investing.com
Best Biotech Stocks Right Now • Updated Daily - Benzinga
Immix Biopharma Inc’s latest rating changes from various analysts - Knox Daily
Q3 2024 Earnings Estimate for Immix Biopharma, Inc. Issued By HC Wainwright (NASDAQ:IMMX) - MarketBeat
HC Wainwright Weighs in on Immix Biopharma, Inc.’s Q3 2024 Earnings (NASDAQ:IMMX) - Defense World
Immix Biopharma, Inc. (NASDAQ:IMMX) Director Carey Ng Purchases 10,000 Shares of Stock - Defense World
Immix Biopharma, Inc. (NASDAQ:IMMX) Director Purchases $18,600.00 in Stock - MarketBeat
Immix Biopharma, Inc. to Post FY2024 Earnings of ($0.61) Per Share, Edison Inv. Res Forecasts (NASDAQ:IMMX) - MarketBeat
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 7.5% in July - MarketBeat
What Makes Immix Biopharma (IMMX) a New Buy Stock - MSN
Immix Biopharma (NASDAQ:IMMX) Rating Reiterated by HC Wainwright - MarketBeat
HC Wainwright Reaffirms Buy Rating for Immix Biopharma (NASDAQ:IMMX) - Defense World
FY2024 Earnings Forecast for Immix Biopharma, Inc. (NASDAQ:IMMX) Issued By Edison Inv. Res - Defense World
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024 - InvestorPlace
Immix Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely? - Simply Wall St
Monitoring Immix Biopharma Inc (IMMX) after recent insider movements - Knox Daily
Jason Hsu Purchases 6,000 Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) Stock - Defense World
Umoja Biopharma's In Situ CAR-T Therapy Cleared for US Trial in Hematologic Malignancies - CGTLive™
Immix Biopharma director Jason Hsu buys $19.5k in company shares - Investing.com
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immix Biopharma Inc Stock (IMMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hsu Jason | Director |
Aug 22 '24 |
Buy |
2.25 |
8,100 |
18,233 |
845,300 |
| Ng Carey | Director |
Aug 16 '24 |
Buy |
1.86 |
10,000 |
18,600 |
20,000 |
| Hsu Jason | Director |
Jul 24 '24 |
Buy |
2.15 |
6,000 |
12,877 |
822,200 |
| Hsu Jason | Director |
Jul 18 '24 |
Buy |
2.07 |
3,200 |
6,639 |
816,200 |
| Rachman Ilya M | CEO and Chairman |
Jun 07 '24 |
Buy |
2.13 |
2,600 |
5,538 |
1,136,259 |
| Morris Gabriel S | CFO |
Jun 07 '24 |
Buy |
2.12 |
2,500 |
5,298 |
285,834 |
| Morris Gabriel S | CFO |
Jun 04 '24 |
Buy |
1.81 |
3,300 |
5,973 |
283,334 |
| Rachman Ilya M | CEO and Chairman |
Jun 04 '24 |
Buy |
1.81 |
3,300 |
5,970 |
1,133,659 |
| Morris Gabriel S | CFO |
May 14 '24 |
Buy |
2.23 |
4,500 |
10,042 |
85,816 |
| Rachman Ilya M | CEO and Chairman |
May 14 '24 |
Buy |
2.25 |
4,300 |
9,660 |
912,000 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):